Okay, I know we just started 2026, but just for a moment, let's dial back the clock to Christmas Eve 1968. I I know, right. Wood paneling, shag carpets.I I get it. I'm seven years old and I'm standing in front of a grainy black and white TV screen. And on that screen, three astronauts are wishing me merry Christmas from, of all places, the moon.I was in absolute awe. This was the Apollo 8 mission, and it was the very first time that we had flown beyond Earth's orbit. And here's the thing, their navigation c ...

Positive expectations can boost the immune system’s response to vaccination, according to new research https://t.co/EkJuQ0MvtIIllustration: The Economist https://t.co/dqa7lKgEKe ...

Positive expectations can boost the immune system’s response to vaccination, according to new research https://t.co/paJFAWMQYy ...

Core Viewpoint - Compass Therapeutics, Inc. is set to present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026, highlighting its focus on developing proprietary antibody-based therapeutics for oncology [1]. Presentation Details - The presentation will take place on January 14, 2026, at 7:30 AM PT, and will be available via webcast [2]. - The presentation will be archived on Compass' Events page for future access [2]. - Investors can schedule one-on-one meetings with Compass on the same day by contacting their J.P. Morgan representative [2]. Investor Meetings - Compass will also host investor meetings during the LifeSci Partners Corporate Access Event on January 12 and 13, 2026, in San Francisco, CA [3]. - Interested investors should reach out to their LifeSci representative to arrange a meeting [3]. Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics to address multiple human diseases [4]. - The company emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - Its product candidates target critical biological pathways necessary for effective anti-tumor responses, including angiogenesis modulation and immune response activation [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].

Core Viewpoint - Compass Therapeutics, Inc. is actively engaging with investors through participation in key healthcare conferences in December 2025, highlighting its focus on oncology and proprietary antibody-based therapeutics [1][2]. Group 1: Upcoming Investor Events - Compass Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:00 AM ET in New York, NY [2]. - The company will also attend the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:00 AM ET in Coral Gables, FL [2]. - Presentations from these events will be archived for 90 days on Compass' Events page, allowing for virtual/replay availability [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology [4]. - The company’s research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - The therapeutic strategies include targeting angiogenesis, inducing immune responses, and overcoming immunosuppressive mechanisms utilized by tumors [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].

Financial Data and Key Metrics Changes - Revenue net of returns for Q3 2025 totaled $146,000, an increase from $126,000 in Q3 2024, while for the nine-month period, it decreased to $302,000 from $600,000 in 2024 [12][13] - Cost of sales increased to $291,000 from $82,000 in the year-ago quarter, primarily due to a $230,000 inventory reserve recorded in Q3 2025 [13] - Gross margins, excluding the inventory reserve, were 42% for Q3 2025 compared to 35% for Q3 2024 [13] - Net loss for Q3 2025 was $2.6 million, compared to $1.4 million for Q3 2024, while the nine-month net loss was $6 million compared to $4.2 million in 2024 [14][15] - Cash and cash equivalents at September 30, 2025, totaled $3.5 million, up from $2 million at December 31, 2024 [15] Business Line Data and Key Metrics Changes - The company is transitioning from the consumer device market to biopharmaceuticals, with a focus on Entolimod and related assets [3][11] - The company recorded reserves for excess and obsolete inventory of $230,000 as part of its exit from the consumer device market [11] - The company has discontinued significant resources toward ClearUP sales, reflecting its strategic shift [12] Market Data and Key Metrics Changes - The company is focusing on building relationships with U.S. and allied governments for Entolimod as a military countermeasure [5][6] - Discussions with BARDA are anticipated to explore stockpiling opportunities for Entolimod [5] Company Strategy and Development Direction - The company has undergone a significant strategic transformation, expanding from bioelectronics to biologic pharmaceuticals with a focus on the immune system [3][4] - The primary commercial opportunity for Entolimod is as a countermeasure for acute radiation syndrome, with plans to advance clinical programs in neutropenia and lymphocyte exhaustion [6][7] - The company is also exploring alternative commercial opportunities for its non-invasive vagus nerve stimulation (VNS) program [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress of the transformation and the potential of Entolimod to deliver clinical benefits across multiple organ systems [7][16] - The company aims to advance value creation activities for shareholders while bringing life-saving treatments to patients [17] Other Important Information - The company has completed the transfer of two INDs for Entolimod, enabling further clinical development [6][16] - A new corporate website has been launched to emphasize the transformed mission and expanded clinical pipeline [12] Q&A Session Summary - No specific Q&A session content was provided in the transcript, thus this section is not applicable.

“They’re effectively the immune system’s peacekeepers.” @natashaloder joins “Babbage” to talk about this year’s Nobel prize in physiology or medicine https://t.co/kI7HS8smJe ...

Awards & Recognition - Immunology field sees three immunologists receive the 2025 award for pioneering discoveries [1] - Discoveries are related to the immune system and autoimmune diseases [1]

Researchers have uncovered how the body’s own immune system may be driving the progression of amyotrophic lateral sclerosis, or ALS. It's a breakthrough that could reshape treatment of the fatal disease. https://t.co/CEFQRP6nPg ...

students, parents, and teachers. It's really a great order. I'm a kind of relaxed parent.I don't even know my son's uh class number. When the teacher asked me which class he is, I I just know he's going to 11. He I didn't even know this number of class.I came here representing a group of people which is baby minor society which be called scientist and I actually have a colleague sitting in the audience me is also my colleague and my good friend. Um so um I feel a little bit embarrassed because my slides are ...